Kainos Medicine

At a glance

Kainos Medicine filed 36 disclosures in the last 12 months, including 1 contract. The most recent key filing was on May 29.

Revenue for 2025 was ₩1.2B, up 98.5% on 2024. It made an operating loss of ₩6.4B. Debt was 44% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩778.4M and operating loss of ₩2.1B.

The 2025 annual report lists 15 employees with an average tenure of 4.2 years and average pay of ₩73.4M. Its 4 directors and auditors were paid ₩103M each on average. It paid no cash dividend for 2025. 이기섭 and related parties held 11.93% at year end.

From the 2025 annual report

Staff: 15 (6 men, 9 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩1.1B. Directors and auditors: 4, paid ₩415M in total.

No cash dividend was paid for 2025.

Largest shareholder

이기섭 holds 8.02%; with 13 related parties the group holds 11.93% of common shares at year end (from 10.48% at the start of the year).

Auditor: 삼덕회계법인 · opinion: Disclaimer of opinion. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary